| MORPHOSYS AG O.N. | 88.96 / +0.54% |
| Date/Time | 10/23 / 08:11 |
| Chg. / Chg.(%) | 0.48 / +0.54% |
| Bid | - |
| Ask | - |
| Open | 88.96 |
| Previous Close | 88.48 |
| High | 88.96 |
| Low | 88.96 |
| Volume [EUR] | 0.00 |
| Volume [Units] | 0 |
| Price fixings | 1 |
| ISIN | DE0006632003 |
| Security | MOR |
| Exchange | Hannover |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 87.840 |  |
|
| Xetra | 88.08 |  |
173,807 |
| London Inter.. | 88.36 | |
172,176 |
| Cboe Europe .. | 88.44 | |
60,329 |
| Turquoise | 88.36 | |
13,338 |
| Cboe Europe .. | 88.38 | |
10,158 |
| TradeGate | 88.520 | |
8,680 |
| Stuttgart | 88.000 | |
1,440 |
| gettex | 87.860 | |
504 |
| Hamburg | 87.90 | |
500 |
| Frankfurt | 87.7400 | |
430 |
| Berlin | 88.08 | |
50 |
| Düsseldorf | 87.44 | |
25 |
| Vienna Globa.. | 88.96 | |
0 |
| Hannover | 88.96 | |
0 |
| München | 89.20 | |
0 |
| SIX Swiss Ex.. | 102.00 | |
|
| Nasdaq Other.. | 119.3750 | 100 | |
| EUREX | Options | ||
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire
Real-time